Demcon, a technology developer and manufacturer, has become a technology partner and co-shareholder in ReGEN Biomedical, a company developing technology to grow biological tissue for regenerative medicine and drug screening. This will also give new impetus to innovative tissue factories, Demcon reported in a press release.
Why you need to know this:
Regenerative medicine aims to prevent or treat diseases and other conditions by regenerating cells, tissues, and entire organs. Regenerative medicine is taking a step toward large-scale clinical applications with stem cell therapy and tissue technology. Holland takes advantage of this with his RegMed XB.
ReGEN is part of the RegMed XB pilot plant. National infrastructure covering the entire chain of development and production of stem cells, mini-organs, tissues and smart (bio) materials. The pilot plant is being established with funding from the National Growth Fund of RegMed XB, a Dutch-Flemish public-private partnership. The advent of Demcon provides an impetus to technological development and scale-up to industrial tissue production. This will bring closer application in pharmaceutical research and medical practice, contributing to the realization of a national pilot plant.
Demcon and Carbion are co-creating to tackle climate change
In the Netherlands alone, around 150 million tons of CO2 disappear into the atmosphere every year.
Pilot line for tissue production in Maastricht
ReGEN Biomedical is an independent company from the research group of University Professor Clemens van Blitterswijk. He is the founder of tissue engineering in Europe and is considered an international leading researcher in the field of tissue repair. ReGEN Biomedical focuses on growing large amounts of functional microtissues as building blocks for clinical applications in macrotissues and even organs. The production line was installed last year at the Brightlands Maastricht Health Campus, partially made possible by funding from the National Growth Fund. The line was officially commissioned in September.
next step
The opening of the pilot line and Demcon's participation heralds the next stage of growth for ReGEN Biomedical, said Dennis Schipper, CEO of Demcon. “Currently, we are committed to continuing technology development, establishing and following a product roadmap, and commercializing our products and production technologies. To this end, we at Demcon are committed to the marketing of medical technologies, especially bioreactors. We draw on our extensive experience in technology development.
